Clinical study of Apatinib combination with SOX as First line treatment in patients with adenocarcinoma of the Stomach or Gastroesophageal Junction

Trial Profile

Clinical study of Apatinib combination with SOX as First line treatment in patients with adenocarcinoma of the Stomach or Gastroesophageal Junction

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2017

At a glance

  • Drugs Apatinib (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top